Ozdemir Oner
Öner Özdemir, Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, Sakarya University, Research and Training Hospital of Sakarya University, Adapazarı, 54100 Sakarya, Turkey.
World J Transplant. 2013 Sep 24;3(3):30-5. doi: 10.5500/wjt.v3.i3.30.
Transplant-acquired allergy (TAA) was firstly described as transplant-acquired food allergy (TAFA) after bone marrow transplantations and mostly observed in a transient form. The picture is complicated by numerous case reports of TAFA after the receipt of liver grafts from donors with no documented history of food allergy. The estimated prevalence of TAFA among young children in the literature has been documented in various studies ranging from 6% to 57%. Although TAA is mostly found to be associated with liver transplantation; it has been recently reported to be related with heart, intestinal, lung and even renal transplantations in adults. Previous reviews of published cases of liver TAA misleadingly emphasized the predominance of children and the absence of TAA in cardiac, pulmonary, and renal transplant recipients. In different studies, the male/female ratio is equal. Literature data suggest that children with TAFA typically present within the first year after surgery and are typically allergic to multiple foods. The pathogenesis of TAA is not still completely understood. Most of the studies support the concept that the functioning liver itself, and not only tacrolimus immunosuppression, is one of the main contributors to TAA in these patients. In the light of recent findings, other possible mechanisms can be summarized as following: (1) the recovery of delayed type hypersensitivity; (2) late manifestation of food allergy; (3) intestinal injury as well as inhibition of cellular energy production by tacrolimus; and (4) transfer of food-specific IgE or lymphocytes. Thus, interplay between hematopoietic cells from the transplanted organ and recipient specific factors (e.g., younger age and atopic background) seem to underlie the development of TAA. Most patients will have symptomatic improvement following reduced immunosuppression and an appropriately restricted diet. Nevertheless, some studies suggest that atopic diseases occur in some of pediatric liver transplant recipients, with manifestations including food allergy, eczema, allergic rhinitis, and asthma. More studies would be needed including greater number of patients to determine whether TAA is transient or not in pediatric/adult solid organ recipients.
移植获得性过敏(TAA)最初在骨髓移植后被描述为移植获得性食物过敏(TAFA),且大多以短暂形式出现。在接受来自无食物过敏记录供体的肝脏移植后出现TAFA的大量病例报告使情况变得复杂。文献中关于幼儿TAFA的估计患病率在不同研究中有所记载,范围从6%到57%不等。尽管TAA大多被发现与肝移植有关,但最近有报道称其在成人中与心脏、肠道、肺甚至肾移植有关。先前对已发表的肝TAA病例的综述错误地强调了儿童的 predominance 以及心脏、肺和肾移植受者中不存在TAA的情况。在不同研究中,男女比例相等。文献数据表明,患有TAFA的儿童通常在手术后第一年内出现,且通常对多种食物过敏。TAA的发病机制仍未完全明确。大多数研究支持这样的观点,即正常运作的肝脏本身,而非仅他克莫司免疫抑制,是这些患者TAA的主要促成因素之一。根据最近的研究结果,其他可能的机制可总结如下:(1)迟发型超敏反应的恢复;(2)食物过敏的晚期表现;(3)肠道损伤以及他克莫司对细胞能量产生的抑制;(4)食物特异性IgE或淋巴细胞的转移。因此,移植器官的造血细胞与受体特异性因素(如年龄较小和特应性背景)之间的相互作用似乎是TAA发生的基础。大多数患者在免疫抑制降低和饮食适当限制后症状会有所改善。然而,一些研究表明,一些小儿肝移植受者会出现特应性疾病,表现包括食物过敏、湿疹、过敏性鼻炎和哮喘。需要进行更多研究,纳入更多患者,以确定TAA在小儿/成人实体器官受者中是否为短暂性。 (注:“predominance”此处可能是“优势、突出情况”等意思,因原词较模糊,按常见理解翻译)